Trial Profile
Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia; Neonatal jaundice
- Focus Expanded access; Therapeutic Use
- Sponsors InfaCare Pharmaceutical Corporation
- 12 Dec 2016 Status changed from recruiting to completed.
- 12 Dec 2016 Status changed from recruiting to completed.
- 28 May 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.